Abstract In this review we discuss the position of electrical neuromodulation as a safe and reversible adjuvant therapy for treatment of patients with chronic cardiac diseases who have become refractory to conventional strategies. In patients with chronic refractory angina, electrical neuromodulation, independent of the applied modality, has shown to reduce complaints of angina, to enhance exercise capacity, to improve quality of life and to employ anti-ischaemic effects. To date, electrical neuromodulation seems to be one of the best adjuvant therapies for these patients. In addition, neuromodulation in the treatment of heart failure and resistant arrhythmias is the subject of several ongoing studies.
expressed in, among other things, symptoms of anxiety and depression [8] .
The exact prevalence and incidence of refractory angina is unknown. However, it has been estimated that at least 200,000 patients are suffering from this condition and another 30,000-50,000 new cases can be diagnosed each year in the USA [8] .
Methods of electrical neurostimulation
In 1965, Melzack and Wall proposed the 'gate control' theory, which provides a scientific base for electrical neuromodulation [9] . In brief, the authors postulated that stimulation of myelinated thick A-fibres modulate ('pain') signals processed in unmyelinated and relatively slow conducting C-fibres, via interneurons in the spinal cord. Braunwald et al. were the first to demonstrate anti-angina and anti-ischaemic effects of stellate ganglion stimulation, implemented through a modified cardiac pacemaker, in 1967 [10] .
Since 1982, transcutaneous electrical nerve stimulation (TENS), which acts through stimulation of peripheral nerves, is acknowledged as an effective non-invasive treatment for patients with refractory angina. Though effective, TENS is often not an appropriate therapy over time, since the gel pads used to fix the electrodes on the chest frequently cause irritant contact dermatitis and come off easily [11] .
Spinal cord stimulation (SCS) was introduced in 1967 [12] . Results of the first study on the anti-angina effects of this technique were published in 1987 [13] . The electrodes are habitually positioned at C7-T2 and connected to a pulse generator (IPG), which is most often implanted at the lateral abdominal side. Activation of the IPG induces paresthesias on the chest, corresponding with the area where angina is experienced.
Subcutaneous electrical nerve stimulation (SENS) is a relatively new and promising method, having potential advantages as alternative to TENS and SCS [14] . SENS electrodes are placed subcutaneously, at the side of the sternum in the area where the patient usually feels angina, and are connected to a pulse generator, which is implanted in the abdominal wall. This technique is easier and less invasive compared with SCS, thus reducing the risk of complications. However, all electrical neuromodulation modalities are reversible, since paresthesias can be withheld at any time and implants can be removed [15] .
Ischaemia of myocytes

Anti-angina and anti-ischaemic effect of electrical neuromodulation
The treatment of stable refractory angina with electrical neuromodulation starts with TENS. If TENS is successful, but adverse events occur, treatment with SCS or SENS is instigated. To date, TENS, SCS and SENS have all been proven to be successful within the armamentarium for the treatment of angina.
Many observational and randomised controlled trials have shown an improvement in exercise capacity, a reduction in complaints of angina and a reduced use of shortacting nitrates. Furthermore, an improved QOL, which can persist over a long period of time, has also been demonstrated [16] . Since many of these studies were carried out with a small number of patients, the results are not always consistent. In this respect, two recent meta-analyses on seven randomised controlled trials with SCS, including over 200 patients, show a significant improvement of both exercise capacity and QOL [17, 18] .
Regarding anti-ischaemic effects of electrical neuromodulation, TENS is reported to cause a reduction of lactate production in concert with ST-segment depression, during pacinginduced angina [19] . Furthermore, SCS was found to reduce ST-segment depression, in conjunction with an improved exercise capacity [17, 20] . In 2006, De Vries et al. observed that pre-emptive stimulation with TENS, when applied before acute coronary occlusion during PCI, results in an improved collateral perfusion [21] . Other investigators have performed radionuclide and positron emission tomography (PET) studies to investigate the effects of SCS on myocardial perfusion [22] .
De Vries and co-workers demonstrate a significant decrease of ST-segment elevation in patients with ST-segment elevated myocardial infarction, following primary PCI during active TENS [20] . Active electrical neuromodulation may subsequently limit the extent of myocardial infarctions. In summary, the anti-ischaemic effects of neurogenic stimulation are thought to be the result of enhancement of ischaemic tolerance of the myocyte, through improvement of both collateral perfusion and myocardial preconditioning [20] .
Finally, electrical neuromodulation is considered a safe therapy since angina is experienced during myocardial infarction, even throughout active electrical neuromodulation [20] , many studies have demonstrated anti-ischaemic properties and because electrical neuromodulation does not seem to influence morbidity and mortality [4, 6, 7] .
Future developments
A neural hierarchy enables the nervous system to optimise and control cardiac functions at the neurocardiac interface, through the so-called intrinsic cardiac nervous system (ICN). Electrical neuromodulation is found to stabilise the ICN, in the presence of ischaemia [23] . In addition, electrical neuromodulation may be further exploited to enable neurons to release the required concentrations of neuro-active chemicals to the jeopardised heart. Basic studies on heart failure have demonstrated that electrical neuromodulation significantly improves cardiac function and reduces the incidence of spontaneous ventricular arrhythmias [24] . Hence, at least seven clinical studies are ongoing to assess the effect of electrical neuromodulation in patients with heart failure (ClinicalTrials.gov).
Final conclusions
Since many studies demonstrate a reduction in frequency and intensity of angina, increased exercise capacity, reduction in myocardial ischaemia and improvement of quality of life, we conclude that electrical neuromodulation is an effective, reversible and safe adjuvant therapy for patients suffering from refractory angina. Therefore, and because conventional therapies fail to improve the debilitating symptoms of the patients, electrical neuromodulation should be considered as adjunct treatment for these patients.
